Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
Duty S.
CNS Drugs · review; journal article · DOI 10.1007/s40263-012-0016-z PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för perampanel. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
16 hitsNew developments in the treatment of partial-onset epilepsy.
Besag FM, Patsalos PN.
Neuropsychiatr Dis Treat · review-article; journal article · DOI 10.2147/ndt.s25099Perampanel Study 207: long-term open-label evaluation in patients with epilepsy.
Rektor I, Krauss GL, Bar M, Biton V, Klapper JA, Vaiciene-Magistris N, Kuba R, Squillacote D, Gee M, Kumar D.
Acta Neurol Scand · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/ane.12001Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, Laurenza A.
Epilepsia · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1528-1167.2012.03638.xPerampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, Yang H, Gee M, Zhu J, Laurenza A.
Epilepsia · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/j.1528-1167.2012.03648.xAdjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.
French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA.
Neurology · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1212/wnl.0b013e3182635735New AMPA antagonists in epilepsy.
Russo E, Gitto R, Citraro R, Chimirri A, De Sarro G.
Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2012.705277Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials.
Gao L, Xia L, Zhao FL, Li SC.
Epilepsy Res · meta-analysis; systematic review; journal article · DOI 10.1016/j.eplepsyres.2012.06.005Recent and future antiepileptic drugs and their impact on cognition: what can we expect?
Mula M.
Expert Rev Neurother · review; journal article · DOI 10.1586/ern.12.51Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.
Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, Yang H, Squillacote D, Edwards HB, Zhu J, Laurenza A.
Neurology · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1212/wnl.0b013e318254473aA novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus.
Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A.
Neurochem Int · journal article · DOI 10.1016/j.neuint.2012.02.035Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.
Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow CW, Ruzicka E, Bibbiani F, Squillacote D, Patten A, Tolosa E.
Clin Neuropharmacol · comparative study; multicenter study; randomized controlled trial; journal article · DOI 10.1097/wnf.0b013e318241520bPerampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease.
Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, Mouradian MM, Oertel WH, Olanow CW, Poewe W, Rascol O, Tolosa E, Squillacote D, Kumar D.
Mov Disord · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/mds.23983Tolerability and safety of perampanel: two randomized dose-escalation studies.
Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D.
Acta Neurol Scand · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/j.1600-0404.2011.01588.xPerampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy.
Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y.
Epilepsia · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1528-1167.2011.03109.xRevisiting AMPA receptors as an antiepileptic drug target.
Rogawski MA.
Epilepsy Curr · research-article; journal article · DOI 10.5698/1535-7511-11.2.56